Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M--Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M--EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with VEU

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VEUFirst Eagle Investment 2015-06-30 Buy 0.01%$48.19 - $51.7
($50.15)
$ 39.92-20%New holding73,800
VEUKen Fisher 2013-03-31 Buy $45.45 - $47.27
($46.5)
$ 39.92-14%New holding9,230
VEUJoel Greenblatt 2011-06-30 Sold Out -0.35%$47.24 - $52.01
($49.43)
$ 39.92-19%Sold Out0
VEUJoel Greenblatt 2011-03-31 Add0.27%$45.42 - $49.81
($48.47)
$ 39.92-18%Add 353.24%23,677
VEUJoel Greenblatt 2010-12-31 Buy 0.08%$45.1 - $49.17
($47.23)
$ 39.92-15%New holding5,224
VEUWilbur Ross 2009-12-31 Sold Out -1.36%$41.6 - $45.36
($43.97)
$ 39.92-9%Sold Out0
VEUWilbur Ross 2009-09-30 Buy 1.36%$34.43 - $43.85
($39.8)
$ 39.920%New holding190,300
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VEU is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VEU: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sartor, RobertSenior Officer 2016-02-05Buy1,400$5.35646.17view
Arrow Capital Management Inc.Director or Senior Officer of Insider or Subsidiar 2016-02-05Buy1,000$5.5625.82view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell19,600$18.95110.66view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell19,700$18.96110.55view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell5,600$18.97110.44view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell12,700$19110.11view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell2,900$18.99110.22view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell2,100$19.05109.55view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell1,600$19.03109.77view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell1,900$19.02109.88view

Quarterly/Annual Reports about VEU:

    News about VEU:

    Articles On GuruFocus.com
    Lululemon: What Is Steve Mandel's Thesis? Feb 07 2016 
    Incompetent Management May Kill GoPro Feb 07 2016 
    Yacktman Fund Comments on Staples Feb 05 2016 
    Yacktman Fund Comments on Apollo Feb 05 2016 
    Yacktman Fund Comments on C.H. Robinson Feb 05 2016 
    Yacktman Fund Comments on PepsiCo Feb 05 2016 
    Yacktman Fund Comments on P&G Feb 05 2016 
    Yacktman Fund Comments on Microsoft Feb 05 2016 
    Auxier Asset Management Year-End 2015 Market Commentary Feb 05 2016 
    On Running a Concentrated Portfolio Feb 05 2016 

    More From Other Websites
    Expectations for Valeant Pharmaceuticals in 2016 Feb 04 2016
    Why Did Valeant Shares Fall after Strong 3Q15 Results? Feb 03 2016
    5 Market-Beating International ETFs YTD Feb 02 2016
    How Recent Events Could Affect Novo Nordisk’s Earnings Jan 26 2016
    How Will Teva Finance the Actavis Acquisition? Jan 21 2016
    How Does Sony Corporation Compare to Its ETFs and Peers? Jan 21 2016
    How Will Sandoz Perform in Novartis’s 4Q15 Earnings? Jan 19 2016
    Organic Growth Boosts Sony’s Stock Jan 07 2016
    The Top 5 International Equity ETFs for 2016 (SCZ, VEU) Jan 07 2016
    These Two Charts Show Global Stock Markets Rolling Over Without Growth Dec 22 2015
    Why Valeant Pharmaceuticals Lowered Its Guidance for 4Q15 Dec 21 2015
    Stocks: The Worst December Since 2002? Dec 14 2015
    Entresto: First-in-Class Angiotensin Receptor Neprilysin Inhibitor Dec 14 2015
    FDA Sets December 29 as Lesinurad’s PDUFA Date Dec 07 2015
    The European Commission Approved Novartis’s Entresto Nov 30 2015
    Novartis: Market Responds to European Commission’s Cosentyx Approval Nov 26 2015
    Novartis Gets Expanded Cosentyx Approval from European Commission Nov 25 2015
    Strategic apathy and the mediocre investor Oct 30 2015
    Alibaba Sets Its Sights on Youku Tudou Oct 21 2015
    How Alibaba Will Benefit from the Acquisition of Youku Tudou? Oct 21 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK